Northwest Biotherapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Northwest Biotherapeutics, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include DCVAX and NORTHWEST BIOTHERAPEUTICS. The owner is based in Bethesda, MD.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
Showing of trademarks Trademarks
Trademark Classifications
Northwest Biotherapeutics, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Northwest Biotherapeutics, Inc. have?
Northwest Biotherapeutics, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 3 registered, 5 abandoned.
What trademark classes does Northwest Biotherapeutics, Inc. file in?
Northwest Biotherapeutics, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Northwest Biotherapeutics, Inc.'s most well-known trademarks?
Northwest Biotherapeutics, Inc.'s registered trademark portfolio includes well-known marks such as DCVAX and NORTHWEST BIOTHERAPEUTICS. These are among 3 currently registered trademarks in the portfolio.
What is Northwest Biotherapeutics, Inc.'s trademark registration success rate?
Northwest Biotherapeutics, Inc. has a 38% trademark registration rate, with 3 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.